Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors
Dazostinag, an intravenous STING agonist, combined with radiation, demonstrated tumor control and enhanced intratumoral immune activation, preclinically. In phase 1b, dazostinag plus pembrolizumab following RT had a manageable safety profile and provided clinical benefit for some heavily pretreated patients with advanced/metastatic solid tumors whose disease had progressed on CPIs.
Authors
- Jiehui Deng (ORCID: https://orcid.org/0000-0001-7986-8643)
- Neil Lineberry (ORCID: https://orcid.org/0000-0001-9156-4423)
- Allison Berger (ORCID: https://orcid.org/0000-0003-1217-2005)
- John P. Gibbs (ORCID: https://orcid.org/0000-0001-8892-7318)
- Camilla L. Christensen (ORCID: https://orcid.org/0009-0007-3313-2615)
- Samanthi A. Perera (ORCID: https://orcid.org/0000-0003-1915-7086)
- David B. Page (ORCID: https://orcid.org/0000-0001-9264-4628)
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Kwok‐Kin Wong (ORCID: https://orcid.org/0000-0001-6323-235X)
- Naamit K. Gerber (ORCID: https://orcid.org/0000-0002-6061-0498)
- Jeffrey J. Raizer (ORCID: https://orcid.org/0009-0003-8469-2509)
- Benjamin T. Cooper (ORCID: https://orcid.org/0000-0002-7044-7989)
- Yu-Chung Huang (ORCID: https://orcid.org/0000-0003-4513-518X)
- Steven J. Chmura (ORCID: https://orcid.org/0000-0001-8851-7108)
- Richard C. Gregory (ORCID: https://orcid.org/0000-0002-5041-1882)
- Vicky A. Appleman (ORCID: https://orcid.org/0000-0002-9132-1322)
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
- Camden Bay (ORCID: https://orcid.org/0000-0001-7197-3465)
- E. Jane Leonard (ORCID: https://orcid.org/0009-0000-6261-2289)
- Daniel J. Olson (ORCID: https://orcid.org/0000-0001-8902-7661)
- Kai Ding (ORCID: https://orcid.org/0000-0002-3508-465X)
- Alexander Parent (ORCID: https://orcid.org/0000-0001-6419-3719)
- Cong Li (ORCID: https://orcid.org/0009-0000-9658-5717)
- Yuan Yuan (ORCID: https://orcid.org/0000-0001-7440-8939)
- A. López (ORCID: https://orcid.org/0009-0003-9329-2814)
- E. Tong (ORCID: https://orcid.org/0009-0003-3229-527X)
- E. Roberts (ORCID: https://orcid.org/0009-0009-9672-0443)
Institutions
- Cedars-Sinai Medical Center (US)
- University of Pittsburgh (US)
- Vanderbilt University (US)
- Providence Portland Medical Center (US)
- University of Chicago (US)
- NYU Langone Health (US)
- Magee-Womens Research Institute (US)
- Dana-Farber Cancer Institute (US)
- UPMC Hillman Cancer Center (US)
- Takeda (United States) (US)
- Vanderbilt Health (US)
- Takeda (Japan) (JP)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0566
- Citations
- 1
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Takeda Pharmaceuticals U.S.A.